Clinical Trial Finds Antidepressant Lowers Severe COVID-19 Risk
Summary: A small randomized trial suggests the antidepressant fluvoxamine may reduce the risk of clinical deterioration and hospitalization for people with early, symptomatic COVID-19. Source: University of Virginia Overview A preliminary clinical trial indicates that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) commonly used as an antidepressant, may help prevent mild COVID-19 from progressing to … Read more